294 PATENT ABSTRACTS

bodies to the hapten for assay use or in the manufacture of vaccines; and (b) a desired poly- peptide product and additional protein from which the desired product may be cleaved; and 3. Methods of preparing synthetic structural genes coding for the expression of mammalian poly- peptides in microbial cloning systems.

4567143

P R O C E S S F O R P R E P A R I N G 4 ' - D E S C H L O R O R E B E C C A M Y C I N

James A Matson assigned to Bristol-Myers Company

4565785

R E C O M B I N A N T D N A M O L E C U L E

A new antitumor antibiotic designated herein as 4'-deschlororebeccamycin is produced by fer- mentation of Nocardia aerocolonigenes ATCC 39243. The new compound possesses anti- bacterial activity and inhibits the growth of tumors in experimental animals.

Walte Gilbert, Stephanie A Broome, Lydia J Villa-Komaroff, Argiris A Efstratiadis assigned to The President and Fellows of Harvard College

A plasmid or phage gene for a periplasmic or extraceUular bacterial protein is cleaved, a double-stranded DNA sequence coding for a selected protein or portion thereof from a eu- karyotic cell such as insulin is inserted in that cleaved gene by recombinant DNA techniques and used to transform a bacterium, and the ex- creted selected protein is collected.

4567141

P L A S M I D V E C T O R S I N C L U D I N G TN904

Ronald H Olsen assigned to Microlife Technics Inc

Cloning vectors are described which include the streptomycin resistance (Smr) determinant derived from Tn904. A single site for the restric- tion endonuclease, AvaI, is present within the Tng04 determinant for Smr. A method is described for preparing the Tn904 containing cloning vectors through transposition of Tn904 to a parent cloning vector and then cloning of the Smr gene into another vector segment. The cloning vector is important for inserting deoxy- ribonucleic acid segments, which encode for various characteristics such as chemical produc- tion, antibiotic resistance or bacterial cell pro- perties, in the Star gene Aval cleaved site and which normally provides a marker for identifica- tion of transformed strains of bacteria.

4567145

C O N T I N U O U S P R O D U C T I O N O F E T H A N O L BY U S E O F

R E S P I R A T I O N D E F I C I E N T M U T A N T Y E A S T

Marcel Faber, Jerome D Bernstein, Matthew Grossman assigned to HRI Inc

This invention provides a process for producing ethanol from a D-sugar in a continuous aerobic environment using a flocculant respiration- deficient mutant of Saccharomyces uvarum in a single stage fermentor with a cell settling tank and cell recycle, at a productivity of more than 50 grams ethanol per liter fermentor volume per hour. The process comprises (a) innoculating a fermentation zone with a respiration-deficient mutant of Saccharomyces uvarum; (b) feeding a mixture of a D-sugar, a nitrogen source, a vitamin source and a mineral source into the fer- mentation zone in the presence of oxygen, and (c) fermenting the D-sugar mixture for a suffic- iently long period of time to yield an ethanol product. In the process, the yeast are allowed to settle for a sufficiently long period of time and recycled to the fermentation zone to increase ethanol productivity. The preferred D-sugar that may be used in the present process to produce ethanol, is D-glucose.

4568542

V A C C I N E C O M P O S I T I O N S

Lee Kronenberg assigned to Lee BioMolecular Research Laboratories lnc

The present invention describes the inactivation of target cells by treatment of said cells with